Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Here is what the fund said: “Alphabet Inc., Eli Lilly and Company, QUALCOMM Incorporated (NASDAQ:QCOM), Microsoft Corporation, and Apple Inc. were the largest detractors. Qualcomm has given back ...

Madison Investments highlighted QCOM in its Q3 2024 investor letter. Here is what the firm has to say: “Alphabet Inc., Eli Lilly and Company, QUALCOMM Incorporated (NASDAQ:QCOM), Microsoft ...

including Eli Lilly's (LLY) declining share price despite topping first quarter earnings estimates, CVS Health's (CVS) recent earnings beat, and chipmaker Qualcomm (QCOM) issuing soft guidance ...

The loss in Eli Lilly has contributed to the underperformance of the S&P 500 health care sector (-2.3%). Cookies are essential for making our site work. By using our site, you consent to the use of ...

Eli Lilly isn't done in developing new weight loss treatments. In fact, the best may still be to come, as it's working on a pill, which could be a game changer for the industry.

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity pill.

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.